Oral graft-versus-host disease

Oral Diseases

Volumn 14, Issue 5, 2008, Pages 396-412

  Imanguli, M M ^a   Alevizos, I ^b   Brown, R ^c   Pavletic, S Z ^a   Atkinson, J C ^b,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c HOWARD UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^d MSC 4878 ^*  (United States)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplant; Salivary gland disease; Xerostomia

Indexed keywords

ACICLOVIR; BECLOMETASONE; BUDESONIDE; CEVIMELINE; CLOBETASOL; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; ETANERCEPT; FLUOCINONIDE; FLUORIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PALIFERMIN; PENTOSTATIN; PILOCARPINE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE; UNINDEXED DRUG; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD TOXICITY; CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PRACTICE; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; EXTRACORPOREAL PHOTOPHORESIS; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HISTOPATHOLOGY; HUMAN; LICHENOID; MEDLINE; MOUTH DISEASE; MOUTH MUCOSA ATROPHY; MOUTH ULCER; MUCOCELE; MYELOABLATIVE CONDITIONING; NONHUMAN; ORAL FIBROSIS; ORAL GRAFT VERSUS HOST DISEASE; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SALIVARY GLAND DISEASE; SJOEGREN SYNDROME; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MOUTH DISEASES;

EID: 45249099752     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2008.01448.x     Document Type: Review

References (132)

1. Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L, Ghavamzadeh A, Tohidast-Acrad Z (2007). Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 39 : 431 434.
2. Albert MH, Becker B, Schuster FR et al (2007). Oral graft vs. host disease in children - treatment with topical tacrolimus ointment. Pediatr Transplant 11 : 306 311.
3. Alborghetti MR, Correa ME, Adam RL et al (2005). Late effects of chronic graft-vs.-host disease in minor salivary glands. J Oral Pathol Med 34 : 486 493.
4. Alpdogan O, Muriglan SJ, Eng JM et al (2003). IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest 112 : 1095 1107.
5. Appelbaum FR (2007). Hematopoietic-cell transplantation at 50. N Engl J Med 357 : 1472 1475.
6. Atkinson JC, Grisius M, Massey W (2005). Salivary hypofunction and xerostomia: diagnosis and treatment. Dent Clin North Am 49 : 309 326.
7. Baird K, Pavletic SZ (2006). Chronic graft versus host disease. Curr Opin Hematol 13 : 426 435.
8. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW (1999). Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 93 : 3267 3275.
9. Biagi JJ, Mileshkin L, Grigg AP, Westerman DW, Prince HM (2001). Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 28 : 1145 1150.
10. Billingham RE (1966). The biology of graft-versus-host reactions. Harvey Lect 62 : 21 78.
11. Blazar BR, Weisdorf DJ, Defor T et al (2006). Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 108 : 3216 3222.
12. Brattstrom C, Tollemar J, Ringden O, Bergstrom K, Tyden G (1991). Isoamylase levels in bone marrow transplant patients are affected by total body irradiation and not by graft-versus-host disease. Transpl Int 4 : 96 98.
13. Carpenter PA, Schubert MM, Flowers ME (2006). Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant 12 : 792 794.
14. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR (2007). Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110 : 3804 3813.
15. Chisholm DM, Mason DK (1968). Labial salivary gland biopsy in Sjogren's disease. J Clin Pathol 21 : 656 660.
16. Choi CJ, Nghiem P (2001). Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol 137 : 1202 1206.
17. Clark FJ, Gregg R, Piper K et al (2004). Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 103 : 2410 2416.
18. Cooke KR, Gerbitz A, Crawford JM et al (2001). LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 107 : 1581 1589.
19. Coracin FL, Pizzigatti Correa ME, Camargo EE et al (2006). Major salivary gland damage in allogeneic hematopoietic progenitor cell transplantation assessed by scintigraphic methods. Bone Marrow Transplant 37 : 955 959.
20. Couriel DR, Saliba RM, Giralt S et al (2004). Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10 : 178 185.
21. Couriel D, Carpenter PA, Cutler C et al (2006). Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12 : 375 396.
22. Curtis RE, Metayer C, Rizzo JD et al (2005). Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 105 : 3802 3811.
23. Cutler C, Miklos D, Kim HT et al (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 : 756 762.
24. Dahllof G, Heimdahl A, Bolme P, Lonnqvist B, Ringden O (1988). Oral condition in children treated with bone marrow transplantation. Bone Marrow Transplant 3 : 43 51.
25. Dens F, Boogaerts M, Boute P et al (1996). Caries-related salivary microorganisms and salivary flow rate in bone marrow recipients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81 : 38 43.
26. Eckardt A, Starke O, Stadler M, Reuter C, Hertenstein B (2004). Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 40 : 811 814.
27. Elad S, Or R, Garfunkel AA, Shapira MY (2003). Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 : 308 311.
28. Epstein JB, Reece DE (1994). Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 13 : 81 86.
29. Epstein JB, Ransier A, Sherlock CH, Spinelli JJ, Reece D (1996). Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Eur J Cancer B Oral Oncol 32B : 158 162.
30. Farmer ER (1985). Human cutaneous graft-versus-host disease. J Invest Dermatol 85 : 124s 128s.
31. Ferrara JL, Reddy P (2006). Pathophysiology of graft-versus-host disease. Semin Hematol 43 : 3 10.
32. Filipovich AH, Weisdorf D, Pavletic S et al (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 : 945 956.
33. Flowers ME, Parker PM, Johnston LJ et al (2002). Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100 : 415 419.
34. Fraser CJ, Bhatia S, Ness K et al (2006). Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 108 : 2867 2873.
35. Fujimaki K, Maruta A, Yoshida M et al (2001). Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant 27 : 1275 1281.
36. Fukushi N, Arase H, Wang B et al (1990). Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proc Natl Acad Sci USA 87 : 6301 6305.
37. Garcia FVMJ, Pascual-Lopez M, Elices M, Dauden E, Garcia-Diez A, Fraga J (2002). Superficial mucoceles and lichenoid graft versus host disease: report of three cases. Acta Derm Venereol 82 : 453 455.
38. Gilman AL, Chan KW, Mogul A et al (2000). Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 6 : 327 334.
39. Goulmy E (1996). Human minor histocompatibility antigens. Curr Opin Immunol 8 : 75 81.
40. Gratwhol AA, Moutsopoulos HM, Chused TM et al (1977). Sjogren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med 87 : 703 706.
41. Grazia Roncarolo M, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006). Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212 : 28 50.
42. Greenspan JS, Daniels TE, Talal N, Sylvester RA (1974). The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 37 : 217 229.
43. Hakim FT, Gress RE (2002). Reconstitution of thymic function after stem cell transplantation in humans. Curr Opin Hematol 9 : 490 496.
44. Harrington LE, Hatton RD, Mangan PR et al (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 : 1123 1132.
45. Heidt PJ, Vossen JM (1992). Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation. J Med 23 : 161 173.
46. Heimdahl A, Johnson G, Danielsson KH, Lonqvist B, Sundelin P, Ringden O (1985). Oral condition of patients with leukemia and severe aplastic anemia. Follow-up 1 year after bone marrow transplantation. Oral Surg Oral Med Oral Pathol 60 : 498 504.
47. Hiroki A, Nakamura S, Shinohara M et al (1996). A comparison of glandular involvement between chronic graft-versus-host disease and Sjogren's syndrome. Int J Oral Maxillofac Surg 25 : 298 307.
48. Horn TD, Rest EB, Mirenski Y, Corio RL, Zahurak ML, Vogelsang GB (1995). The significance of oral mucosal and salivary gland pathology after allogeneic bone marrow transplantation. Arch Dermatol 131 : 964 965.
49. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC (2006). Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101 : 175 183.
50. Imanguli MM, Atkinson JC, Harvey KE et al (2007). Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol 35 : 184 192.
51. Izutsu KT, Schubert MM, Truelove EL et al (1983a). The predictive value of elevated labial saliva sodium concentration: its relation to labial gland pathology in bone marrow transplant recipients. Hum Pathol 14 : 29 35.
52. Izutsu KT, Sullivan KM, Schubert MM et al (1983b). Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. Transplantation 35 : 441 446.
53. Izutsu KT, Menard TW, Schubert MM et al (1985). Graft versus host disease-related secretory immunoglobulin A deficiency in bone marrow transplant recipients. Findings in labial saliva. Lab Invest 52 : 292 297.
54. Janin-Mercier A, Devergie A, Arrago JP et al (1987). Systemic evaluation of Sjogren-like syndrome after bone marrow transplantation in man. Transplantation 43 : 677 679.
55. Kim SS (2007). Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. Ann Pharmacother 41 : 1436 1444.
56. Kolb HJ, Socie G, Duell T et al (1999). Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 131 : 738 744.
57. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J (2005). Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 84 : 681 685.
58. Kyewski B, Klein L (2006). A central role for central tolerance. Annu Rev Immunol 24 : 571 606.
59. Lalla RV, Sonis ST, Peterson DP (2008). Management of oral mucositis in patients who have cancer. Dent Clin North Am 52 : 61 77.
60. Laughlin MJ, Eapen M, Rubinstein P et al (2004). Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 : 2265 2275.
61. Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB (1977). Scleroderma, Sjogren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med 87 : 707 709.
62. Lew J, Smith J (2007). Mucosal graft-vs-host disease. Oral Dis 13 : 519 529.
63. Lindahl G, Lonnquist B, Hedfors E (1988). Lymphocytic infiltration and HLA-DR expression of salivary glands in bone marrow transplant recipients: a prospective study. Clin Exp Immunol 72 : 267 273.
64. Ljungman P, de La Camara R, Milpied N et al (2002). Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99 : 3050 3056.
65. Loughran TP, Jr., Sullivan K, Morton T et al (1990). Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76 : 228 234.
66. Mackay F, Silveira PA, Brink R (2007). B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 19 : 327 336.
67. Mak TWSM (2006). The immune response. Basic and clinical principles. Elsevier : London.
68. Marmont AM, Horowitz MM, Gale RP et al (1991). T-cell depletion of HLA-identical transplants in leukemia. Blood 78 : 2120 2130.
69. Miklos DB, Kim HT, Miller KH et al (2005). Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105 : 2973 2978.
70. Mohty M, Kuentz M, Michallet M et al (2002). Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 100 : 3128 3134.
71. Nagler RM, Nagler A (1999). Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Bone Marrow Transplant 23 : 1007 1011.
72. Nagler RM, Nagler A (2001). The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. Arch Oral Biol 46 : 689 695.
73. Nagler RM, Nagler A (2004). The molecular basis of salivary gland involvement in graft - vs. - host disease. J Dent Res 83 : 98 103.
74. Nagler R, Marmary Y, Krausz Y, Chisin R, Markitziu A, Nagler A (1996). Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 17 : 219 224.
75. Nakamura S, Hiroki A, Shinohara M et al (1996). Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82 : 556 563.
76. Nakhleh RE, Miller W, Snover DC (1989). Significance of mucosal vs salivary gland changes in lip biopsies in the diagnosis of chronic graft-vs-host disease. Arch Pathol Lab Med 113 : 932 934.
77. Nash RA, McSweeney PA, Nelson JL et al (2006). Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum 54 : 1982 1986.
78. Neudorf S, Sanders J, Kobrinsky N et al (2004). Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103 : 3655 3661.
79. O'Keefe CL, Gondek L, Davis R et al (2007). Molecular analysis of alloreactive CTL post-hemopoietic stem cell transplantation. J Immunol 179 : 2013 2022.
80. Okamoto M, Okano A, Akamatsu S et al (2006). Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 20 : 172 173.
81. Parker PM, Chao N, Nademanee A et al (1995). Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 86 : 3604 3609.
82. Patriarca F, Skert C, Sperotto A et al (2006). The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 34 : 389 396.
83. Pavletic SZ, Illei GG (2005). The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 19 : 839 858.
84. Pavletic SZ, Smith LM, Bishop MR et al (2005). Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol 78 : 265 274.
85. Pavletic SZ, Martin P, Lee SJ et al (2006). Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 12 : 252 266.
86. Piboonniyom SO, Treister N, Pitiphat W, Woo SB (2005). Scoring system for monitoring oral lichenoid lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 : 696 703.
87. Przepiorka D, Anderlini P, Saliba R et al (2001). Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98 : 1695 1700.
88. Radfar L, Kleiner DE, Fox PC, Pillemer SR (2002). Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 47 : 520 524.
89. Ratanatharathorn V, Carson E, Reynolds C et al (2000). Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 133 : 275 279.
90. Ratanatharathorn V, Ayash L, Reynolds C et al (2003). Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9 : 505 511.
91. Reddy P, Ferrara JLM (2003). Immunobiology of acute graft-versus-host disease. Blood Rev 17 : 187 194.
92. Rieger K, Loddenkemper C, Maul J et al (2006). Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 107 : 1717 1723.
93. Roncarolo M-G, Battaglia M (2007). Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7 : 585 598.
94. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E (1988). Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 46 : 238 240.
95. Sakaguchi S (2004). Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 : 531 562.
96. Sale GE, Shulman HM, Schubert MM et al (1981). Oral and ophthalmic pathology of graft versus host disease in man: predictive value of the lip biopsy. Hum Pathol 12 : 1022 1030.
97. Saliba RM, de Lima M, Giralt S et al (2007). Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 109 : 2751 2758.
98. Sarantopoulos S, Stevenson KE, Kim HT et al (2007). High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 13 : 6107 6114.
99. Sari I, Altuntas F, Kocyigit I et al (2007). The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 82 : 349 356.
100. Sasazuki T, Juji T, Morishima Y et al (1998). Effect of matching of Class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 339 : 1177 1185.
101. Schubert MM, Correa ME (2008). Oral graft-versus-host disease. Dent Clin North Am 52 : 79 109.
102. Schubert MM, Sullivan KM (1990). Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 9 : 135 143.
103. Schwartz RH (2003). T cell anergy. Annu Rev Immunol 21 : 305 334.
104. Shimada K, Yokozawa T, Atsuta Y et al (2005). Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant 36 : 115 121.
105. Ship JA, Fox PC, Baum BJ (1991). How much saliva is enough? 'Normal' function defined. J Am Dent Assoc 122 : 63 69.
106. Shlomchik WD (2003). Antigen presentation in graft-vs-host disease. Exp Hematol 31 : 1187 1197.
107. Shlomchik WD (2007). Graft-versus-host disease. Nat Rev Immunol 7 : 340 352.
108. Shulman HM, Sullivan KM, Weiden PL et al (1980). Chronic graft-versus-host syndrome in man. A long term clinicopathologic study of 20 Seattle patients. Am J Med 69 : 204 217.
109. Shulman HM, Kleiner D, Lee SJ et al (2006). Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 12 : 31 47.
110. Soares AB, Faria PR, Magna LA et al (2005). Chronic GVHD in minor salivary glands and oral mucosa: histopathological and immunohistochemical evaluation of 25 patients. J Oral Pathol Med 34 : 368 373.
111. Spielberger R, Stiff P, Bensinger W et al (2004). Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 : 2590 2598.
112. Steinbrenner M, Hafer R, Gruhn B et al (2005). T-cell independent production of salivary secretory IgA after hematopoietic stem cell transplantation in children. Oral Microbiol Immunol 20 : 282 288.
113. Sun Y, Tawara I, Toubai T, Reddy P (2007). Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 150 : 197 214.
114. Svegliati S, Olivieri A, Campelli N et al (2007). Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110 : 237 241.
115. Syrjanen S (1984). Age-related changes in structure of labial minor salivary glands. Age Ageing 13 : 159 165.
116. Tarpley TM, Jr., Anderson LG, White CL (1974). Minor salivary gland involvement in Sjogren's syndrome. Oral Surg Oral Med Oral Pathol 37 : 64 74.
117. Thomas X, Boiron JM, Huguet F et al (2004). Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22 : 4075 4086.
118. Tichelli A, Duell T, Weiss M et al (1996). Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant 17 : 1105 1111.
119. Treister NS, Woo SB, O'Holleran EW, Lehmann LE, Parsons SK, Guinan EC (2005). Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 : 721 731.
120. Treister NS, Cook EF, Jr., Antin J, Lee SJ, Soiffer R, Woo S-B (2008). Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 14 : 110 115.
121. Ueno NT, Childs RW (2007). What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. Biol Blood Marrow Transplant 13 : 31 33.
122. Vitali C, Bombardieri S, Jonsson R et al (2002). Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 : 554 558.
123. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M (2005). Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 27 : 247 249.
124. Wolff D, Anders V, Corio R et al (2004). Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed 20 : 184 190.
125. Woo SB, Lee SJ, Schubert MM (1997). Graft-vs.-host disease. Crit Rev Oral Biol Med 8 : 201 216.
126. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS (2005). Leukocyte migration and graft-versus-host disease. Blood 105 : 4191 4199.
127. Yamashita K, Choi U, Woltz PC et al (2004). Severe chronic graft-versus-host disease is characterized by a preponderance of CD4+ effector memory cells relative to central memory cells. Blood 103 : 3986 3988.
128. Yamashita K, Horwitz ME, Kwatemaa A et al (2006). Unique abnormalities of CD4+ and CD8+ central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. Biol Blood Marrow Transplant 12 : 22 30.
129. Yeh CK, Johnson DA, Dodds MW (1998). Impact of aging on human salivary gland function: a community-based study. Aging (Milano) 10 : 421 428.
130. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR (1996). Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 107 : 235 242.
131. Zaja F, Bacigalupo A, Patriarca F et al (2007). Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40 : 273 277.
132. Zorn E, Kim HT, Lee SJ et al (2005). Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106 : 2903 2911.